These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 35866830)

  • 1. Is the glucocorticoid receptor a key player in prostate cancer?: A literature review.
    Sakellakis M; Flores LJ
    Medicine (Baltimore); 2022 Jul; 101(29):e29716. PubMed ID: 35866830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
    Li C; Han X; Yan Q; Ji Y; Zhang R; Yuan D; Yang F; Wang J; Wu M; Zhou J
    J Med Chem; 2024 Mar; 67(5):3419-3436. PubMed ID: 38385428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Puhr M; Eigentler A; Handle F; Hackl H; Ploner C; Heidegger I; Schaefer G; Brandt MP; Hoefer J; Van der Pluijm G; Klocker H
    Oncogene; 2021 Apr; 40(17):3087-3100. PubMed ID: 33795839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
    Puhr M; Hoefer J; Eigentler A; Ploner C; Handle F; Schaefer G; Kroon J; Leo A; Heidegger I; Eder I; Culig Z; Van der Pluijm G; Klocker H
    Clin Cancer Res; 2018 Feb; 24(4):927-938. PubMed ID: 29158269
    [No Abstract]   [Full Text] [Related]  

  • 5. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
    Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
    Elife; 2019 Dec; 8():. PubMed ID: 31855178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
    Arora VK; Schenkein E; Murali R; Subudhi SK; Wongvipat J; Balbas MD; Shah N; Cai L; Efstathiou E; Logothetis C; Zheng D; Sawyers CL
    Cell; 2013 Dec; 155(6):1309-22. PubMed ID: 24315100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
    Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
    Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
    Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells.
    Sahu B; Laakso M; Pihlajamaa P; Ovaska K; Sinielnikov I; Hautaniemi S; Jänne OA
    Cancer Res; 2013 Mar; 73(5):1570-80. PubMed ID: 23269278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
    Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
    Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease.
    Smith R; Liu M; Liby T; Bayani N; Bucher E; Chiotti K; Derrick D; Chauchereau A; Heiser L; Alumkal J; Feiler H; Carroll P; Korkola JE
    Sci Rep; 2020 Dec; 10(1):21750. PubMed ID: 33303959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid Receptor (GR) Activation Is Associated with Increased cAMP/PKA Signaling in Castration-Resistant Prostate Cancer.
    Bennett L; Jaiswal PK; Harkless RV; Long TM; Gao N; Vandenburg B; Selman P; Durdana I; Lastra RR; Vander Griend D; Adelaiye-Ogala R; Szmulewitz RZ; Conzen SD
    Mol Cancer Ther; 2024 Apr; 23(4):552-563. PubMed ID: 38030378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
    Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
    Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromatin accessibility and pioneer factor FOXA1 restrict glucocorticoid receptor action in prostate cancer.
    Helminen L; Huttunen J; Tulonen M; Aaltonen N; Niskanen EA; Palvimo JJ; Paakinaho V
    Nucleic Acids Res; 2024 Jan; 52(2):625-642. PubMed ID: 38015476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reappraisal of glucocorticoids in castrate-resistant prostate cancer.
    Sartor O; Parker CC; de Bono J
    Asian J Androl; 2014; 16(5):666. PubMed ID: 24994787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and characterization of castration-resistant prostate cancer LNCaP95 clones.
    Leung JK; Tam T; Wang J; Sadar MD
    Hum Cell; 2021 Jan; 34(1):211-218. PubMed ID: 32954481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer.
    Shah N; Wang P; Wongvipat J; Karthaus WR; Abida W; Armenia J; Rockowitz S; Drier Y; Bernstein BE; Long HW; Freedman ML; Arora VK; Zheng D; Sawyers CL
    Elife; 2017 Sep; 6():. PubMed ID: 28891793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality.
    Yemelyanov A; Bhalla P; Yang X; Ugolkov A; Iwadate K; Karseladze A; Budunova I
    Cell Cycle; 2012 Jan; 11(2):395-406. PubMed ID: 22223138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
    Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
    Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.